Tesamorelin side effects and safety data

Tesamorelin (brand name Egrifta, Egrifta SV) is a growth hormone-releasing hormone analogue approved by the US FDA for HIV-associated lipodystrophy. Because the drug raises circulating IGF-1 and causes systemic hormonal changes, its side effect profile differs from most peptides discussed on this site. This article draws on the FDA-approved prescribing label^[1] and pooled data from the pivotal phase-3 trials submitted to the FDA^[2]. Outside the United States, tesamorelin has no marketing authorisation: the European Medicines Agency withdrew its application in 2012 following CHMP concerns about IGF-1 elevation, potential malignancy risk, and worsening of diabetic retinopathy.

Common adverse reactions: what the label reports

The EGRIFTA SV prescribing information lists adverse reactions occurring in at least 5% of tesamorelin-treated patients (n=543) versus placebo (n=263) across the controlled trials^[1]. The most frequently reported events were:

Injection site reactions (erythema, pruritus, pain): 17% with tesamorelin versus 6% with placebo. Arthralgia: 13% versus 11%. Pain in extremity: 6% versus 5%. Myalgia: 6% versus 2%. Peripheral edema: 6% versus 2%. Paresthesia: 5% versus 2%.^[1]

Injection site reactions were the single most common reason patients discontinued the drug. Most resolved without intervention. The label notes that fluid retention effects, including edema and arthralgia, may be transient or may require dose adjustment or discontinuation.

Metabolic concerns: glucose and IGF-1

Tesamorelin raises circulating growth hormone (GH), which in turn raises insulin-like growth factor 1 (IGF-1). In the controlled trials, 47% of 26-week tesamorelin recipients had IGF-1 levels above 2 standard deviation scores (SDS), and 36% exceeded 3 SDS^[1]. The clinical consequences of sustained IGF-1 elevation are not fully established. The label states that prolonged elevated IGF-1 carries unknown long-term effects and advises discontinuing the drug if persistent elevations occur.

Glucose metabolism is also affected. In the trials, 5% of tesamorelin-treated patients developed an HbA1c of 6.5% or higher from baseline by week 26, compared with 1% in the placebo group (hazard ratio 3.3; 95% CI 1.4 to 9.6)^[1]. The pooled phase-3 analysis noted no clinically meaningful differences in glucose parameters at weeks 26 and 52 overall^[2], but the label's hazard ratio reflects a real signal for new-onset dysglycemia in susceptible patients. Anyone with pre-existing insulin resistance or prediabetes carries a higher baseline risk.

For patients with diabetes, the label requires monitoring at regular intervals for the development or worsening of diabetic retinopathy. IGF-1 stimulates retinal vessel growth, and the CHMP cited this concern as one reason the European application was not approved.^[1]

Serious adverse events and the malignancy question

Tesamorelin stimulates GH release and raises IGF-1. Both GH and IGF-1 are known growth factors with theoretical potential to promote tumour growth. The FDA label does not include a boxed warning for malignancy, but it does require that providers weigh benefit versus risk for patients with a history of cancer, and discontinue the drug if there is any evidence of recurrent malignancy^[1]. The pivotal trials enrolled HIV-positive adults with lipodystrophy, a population already at elevated cancer background risk, so isolating tesamorelin's independent contribution is methodologically difficult.

In the original phase-2 randomised trial published in the New England Journal of Medicine, adverse events did not differ significantly between treatment and placebo groups overall, but more patients in the tesamorelin group withdrew due to an adverse event^[3]. The pooled phase-3 analysis confirmed the drug was generally well tolerated across 26 and 52 weeks of follow-up^[2]. No trial has been powered specifically to detect rare serious adverse events such as malignancy.

Who should not use tesamorelin

The FDA label lists four absolute contraindications^[1]: (1) disruption of the hypothalamic-pituitary axis from any cause, including hypophysectomy, hypopituitarism, pituitary tumour or surgery, head irradiation, or head trauma; (2) active malignancy; (3) known hypersensitivity to tesamorelin or excipients; (4) pregnancy, because modifying visceral adipose tissue offers no benefit during pregnancy and could cause fetal harm. The label also advises caution in patients with diabetes, given the glucose and retinopathy signals described above.

What we do not yet know

The trials that supported FDA approval enrolled HIV-positive adults receiving antiretroviral therapy and enrolled participants for a maximum of 52 weeks. Long-term safety data beyond one year are limited. Whether the IGF-1 elevation translates into meaningful cancer risk over a decade of treatment is unanswered. The effect of tesamorelin in people without HIV-associated lipodystrophy has not been studied in the pivotal trials, and the label's safety data should not be extrapolated to other populations.

Outside the US, the drug is not approved. Individuals sourcing tesamorelin through grey-market channels face additional uncertainty: no regulatory authority oversees the purity or dosing accuracy of such products, and the manufacturing standards that underpinned the trial safety data would not apply. Other GHRH-related peptides used in research settings, such as ipamorelin, carry their own distinct profiles and have not undergone the same regulatory review process.

This article is for educational purposes only. It summarises what the regulatory label and published trials report about tesamorelin's adverse event profile. It is not a substitute for medical advice. Anyone considering tesamorelin, or currently taking it, should discuss their individual risk factors with a qualified healthcare provider. For a broader overview of tesamorelin's mechanism and approved uses, see our tesamorelin peptide page.